Biological properties of natural dyes

El propósito del presente trabajo es evaluar el aumento en el uso de colorantes naturales en la industria alimentaria y la posibilidad de desarrollar nuevos medicamentos gracias a sus diversas propiedades biológicas. La presente revisión aborda las principales actividades biológicas observadas en los carotenoides y las antocianinas y pone énfasis en el amplio uso del extracto de achiote o bija (Bixa orellana L.) y de la curcumina (Curcuma longa) en estas actividades.The aim of the present work is to evaluate the increase uses of natural colorants in the nourishing industry and in the promising of new medicines due its several biological properties. In this review the main biological activities observed in the carotenóids and the anthocyianins are boarded, with emphasis in the wide use of the urucum‘s extract from Bixa orellana L.) and of curcumin from Curcuma longa in these activities

Biological properties of natural dyes

El propósito del presente trabajo es evaluar el aumento en el uso de colorantes naturales en la industria alimentariay la posibilidad de desarrollar nuevos medicamentos gracias a sus diversas propiedades biológicas. La presenterevisión aborda las principales actividades biológicas observadas en los carotenoides y las antocianinas y poneénfasis en el amplio uso del extracto de achiote o bija (Bixa orellana L.) y de la curcumina (Curcuma longa) en estasactividadesThe aim of the present work is to evaluate the increase uses of natural colorants in the nourishing industry and in thepromising of new medicines due its several biological properties. In this review the main biological activities observedin the carotenóids and the anthocyianins are boarded, with emphasis in the wide use of the urucum‘s extract from Bixaorellana L.) and of curcumin from Curcuma longa in these activities

Genetic Ancestry, Race, and Severity of Acutely Decompensated Cirrhosis in Latin America

Background & Aims: Genetic ancestry or racial differences in health outcomes exist in diseases associated with systemic inflammation (eg, COVID-19). This study aimed to investigate the association of genetic ancestry and race with acute-on-chronic liver failure (ACLF), which is characterized by acute systemic inflammation, multi-organ failure, and high risk of short-term death. / Methods: This prospective cohort study analyzed a comprehensive set of data, including genetic ancestry and race among several others, in 1274 patients with acutely decompensated cirrhosis who were nonelectively admitted to 44 hospitals from 7 Latin American countries. / Results: Three hundred ninety-five patients (31.0%) had ACLF of any grade at enrollment. Patients with ACLF had a higher median percentage of Native American genetic ancestry and lower median percentage of European ancestry than patients without ACLF (22.6% vs 12.9% and 53.4% vs 59.6%, respectively). The median percentage of African genetic ancestry was low among patients with ACLF and among those without ACLF. In terms of race, a higher percentage of patients with ACLF than patients without ACLF were Native American and a lower percentage of patients with ACLF than patients without ACLF were European American or African American. In multivariable analyses that adjusted for differences in sociodemographic and clinical characteristics, the odds ratio for ACLF at enrollment was 1.08 (95% CI, 1.03–1.13) with Native American genetic ancestry and 2.57 (95% CI, 1.84–3.58) for Native American race vs European American race. / Conclusions: In a large cohort of Latin American patients with acutely decompensated cirrhosis, increasing percentages of Native American ancestry and Native American race were factors independently associated with ACLF at enrollment

La construcción de la Agroecología en el Movimiento de los Pequeños Agricultores (MPA) : Un enfoque en el semi-árido brasileño

36 páginasTrabajo fin de Máster dirigido por Eduardo Sevilla Guzmán y tutor Canrobert Costa Neto. Esta investigación se centra en el estudio del desarrollo de la construcción de la agroecología mientras el proceso de la resistencia de los agricultores campesinos del Movimiento de los Pequeños Agricultores (MPA), en particular los del semiárido, “sertão” de la región del nordeste de Brasil. El interés tiene suya razón en el hecho del MPA tener realizado con los demás movimientos sociales de la Vía Campesina de Brasil, estudios sobre el desarrollo del campesinado brasileño y en la necesidad de se mejor conocer las características socio-culturales regionales y el proceso histórico de la resistencia campesina para ampliar y consolidar suya acción en la región, para fijar el hombre en el campo desde el “redescubrimiento” del conocimiento tradicional y del cambio de las experiencias en la convivencia con el semiárido

As plantas medicinais no Centro Agrícola Demonstrativo de Porto Alegre

03

As plantas medicinais no Centro Agrícola Demonstrativo de Porto Alegre

03

Edoxaban versus warfarin in patients with atrial fibrillation

Contains fulltext : 125374.pdf (publisher's version ) (Open Access)BACKGROUND: Edoxaban is a direct oral factor Xa inhibitor with proven antithrombotic effects. The long-term efficacy and safety of edoxaban as compared with warfarin in patients with atrial fibrillation is not known. METHODS: We conducted a randomized, double-blind, double-dummy trial comparing two once-daily regimens of edoxaban with warfarin in 21,105 patients with moderate-to-high-risk atrial fibrillation (median follow-up, 2.8 years). The primary efficacy end point was stroke or systemic embolism. Each edoxaban regimen was tested for noninferiority to warfarin during the treatment period. The principal safety end point was major bleeding. RESULTS: The annualized rate of the primary end point during treatment was 1.50% with warfarin (median time in the therapeutic range, 68.4%), as compared with 1.18% with high-dose edoxaban (hazard ratio, 0.79; 97.5% confidence interval [CI], 0.63 to 0.99; P<0.001 for noninferiority) and 1.61% with low-dose edoxaban (hazard ratio, 1.07; 97.5% CI, 0.87 to 1.31; P=0.005 for noninferiority). In the intention-to-treat analysis, there was a trend favoring high-dose edoxaban versus warfarin (hazard ratio, 0.87; 97.5% CI, 0.73 to 1.04; P=0.08) and an unfavorable trend with low-dose edoxaban versus warfarin (hazard ratio, 1.13; 97.5% CI, 0.96 to 1.34; P=0.10). The annualized rate of major bleeding was 3.43% with warfarin versus 2.75% with high-dose edoxaban (hazard ratio, 0.80; 95% CI, 0.71 to 0.91; P<0.001) and 1.61% with low-dose edoxaban (hazard ratio, 0.47; 95% CI, 0.41 to 0.55; P<0.001). The corresponding annualized rates of death from cardiovascular causes were 3.17% versus 2.74% (hazard ratio, 0.86; 95% CI, 0.77 to 0.97; P=0.01), and 2.71% (hazard ratio, 0.85; 95% CI, 0.76 to 0.96; P=0.008), and the corresponding rates of the key secondary end point (a composite of stroke, systemic embolism, or death from cardiovascular causes) were 4.43% versus 3.85% (hazard ratio, 0.87; 95% CI, 0.78 to 0.96; P=0.005), and 4.23% (hazard ratio, 0.95; 95% CI, 0.86 to 1.05; P=0.32). CONCLUSIONS: Both once-daily regimens of edoxaban were noninferior to warfarin with respect to the prevention of stroke or systemic embolism and were associated with significantly lower rates of bleeding and death from cardiovascular causes. (Funded by Daiichi Sankyo Pharma Development; ENGAGE AF-TIMI 48 ClinicalTrials.gov number, NCT00781391.)